Bionano genomics news.

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million aggregate principal amount of …

Bionano genomics news. Things To Know About Bionano genomics news.

30 Des 2020 ... Bionano Genomics (BNGO) stock is on the move Wednesday with heavy trading following an update from the Nasdaq about its listing status.Sep 30, 2022 · Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended Business Updates Since the End of Q3 2023 Q3 2023 Highlights 6,176 nanochannel array flowcells sold during the third quarter Initiated early access program for Stratys™ system , which are ongoing, $1,863.22 Q4 revenue was $8.2 million, which represents a 30% increase over Q4 2021; 2022 revenue was $27.8 million, which represents a 55% increase over year end 2021; Reached installed base of 240 Saphyr® systems as of YE 2022, which represents a 46% increase over YE 2021; Conference call today, March 9 th, 2023 at 4:30 PM ET SAN …About Bionano Genomics Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing ...

Read the latest breaking news from Bionano Genomics. Find out if Bionano Genomics is biased and reliable and if their media bias is left, center, or right. Get access to our best features. Get Started. Enable Notifications Browser Extension Show Grayscale Images. Wednesday, November 22, 2023 Set Location. US Edition. Home. …Latest news about Bionano Genomics, Inc. North American Morning Briefing : Caution -2- Nov. 14: DJ Transcript : Bionano Genomics, Inc., Q3 2023 Earnings Call, Nov 08, 2023 Nov. 08: CI Bionano Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 Nov. 08: CI Bionano …

Forward-Looking Statements of Bionano Genomics. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as ...CONTACTS. SAN DIEGO , Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 5 p.m. ET on August 4, 2023.

For full-year 2023, Bionano reiterated its revenue guidance of $35.0 million to $38.0 million. The company’s Q2 revenues are expected to be in the range of $7.8 million to $8.3 million. In early morning trading on the Nasdaq, Bionano's shares were up about 7 percent at $.79.Recent News & Activity. ... Bionano Genomics' Saphyr system uses a technology called optical genome mapping (OGM) to analyze long DNA molecules. OGM allows for the direct visualization and analysis of structural variations in the genome without the need for sequencing. This technology can provide valuable insights into the structural variations in …Headline. After Plunging -23.84% in 4 Weeks, Here's Why the Trend Might Reverse for Bionano Genomics, Inc. (BNGO) finance.yahoo.com - November 17 at 2:20 PM. Analysts Offer Insights on Healthcare Companies: BioNano Genomics (BNGO) and Ascendis Pharma (ASND) markets.businessinsider.com - November 16 at 11:51 PM.Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 [email protected] Investor Relations: David Holmes Gilmartin Group +1 (858) 888-7625 [email protected] Genomics News: This is the News-site for the company Bionano Genomics on Markets Insider Indices Commodities Currencies Stocks

Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...

Bionano Genomics. May 9, 2023 at 4:01 PM · 17 min read. Bionano Genomics. Q1 2023 revenue was $7.4 million, which represents a 30% increase over Q1 2022. Installed base of 259 Saphyr® systems ...

Bionano Genomics, Inc. (NASDAQ:BNGO) Q3 2023 Earnings Call Transcript Reported EPS is $-1 EPS, expectations were $-0.75. Operator: Good day, and welcome to the …View the latest Bionano Genomics Inc. (BNGO) stock price, news, historical charts, analyst ratings and financial information from WSJ.NEW YORK – Bionano Genomics this week executed a new round of layoffs, GenomeWeb has learned. According to information obtained by GenomeWeb from former employees who wished to remain anonymous, the workforce reduction appears to impact around 60 employees, although company executives declined to comment.Bionano Genomics Q3 Revenues Grow 29 Percent. In line with its previous estimate, the San Diego-based optical genome mapping company reported $9.3 million in revenues, compared to $7.2 million a year ago.Jun 12, 2023 · Submissions focused on a variety of applications including genetic disease, cancer, reproductive health, cell and gene therapy, and plant and animal research. SAN DIEGO, June 12, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the 2023 winners of its Innovator Research Grant program, including grand prize winner Dr ...

9 Mei 2023 ... News Release Details. « Back. Bionano Reports First Quarter 2023 ... Bionano Genomics is a provider of genome analysis solutions that can ...Mar 31, 2023 · Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. Mar 9, 2023 · According to data from Benzinga Pro, BioNano Genomics is trading lower by 1.6% to $1.23. BNGO has a 52-week high of $4.35 and a 52-week low of $1.16. Photo via Shutterstock. Albino parakeets are those that exhibit a mutation in the color-producing portion of their genome. The gene that causes the mutation is called the ino gene. However, because there are two different basic colorations for parakeets—blue and...Q4 revenue was $8.2 million, which represents a 30% increase over Q4 2021; 2022 revenue was $27.8 million, which represents a 55% increase over year end 2021; Reached installed base of 240 Saphyr® systems as of YE 2022, which represents a 46% increase over YE 2021; Conference call today, March 9 th, 2023 at 4:30 PM ET SAN …Sep 21, 2023 · SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that its Chinese OEM partner, Ecobono, a distribution company focused on reproductive health products, has obtained reagent Class I registration from China's NMPA for Bionano's DNA isolation products. Ecobono is Bionano’s third Chinese OEM ...

SAN DIEGO, April 13, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the American Association for Cancer Research (AACR) Annual Meeting 2023 ...

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine.SAN DIEGEO, May 05, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of NxClinical™ software, a leading solution for visualization, interpretation and reporting of genomic data, today reported financial results for the first quarter ended ...SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million aggregate principal amount of senior secured convertible notes ...SAN DIEGO and RENO, Nev., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Hamilton and Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that the Long String VANTAGE, a system for automated, high throughput isolation of ultra high molecular weight (UHMW) DNA for use in optical genome mapping (OGM) is commercially …BIONANO GENOMICS : Oppenheimer Adjusts Bionano Genomics' PT to $15 From $1.50, Citing Balance Sheet Expansion, Potential of $100 Genome; Outperform Rating Kept 2021: MT BIONANO GENOMICS : Roth Capital Downgrades Bionano Genomics to Neutral From Buy; Price Target is $0.75 2020Sep 21, 2023 · SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that its Chinese OEM partner, Ecobono, a distribution company focused on reproductive health products, has obtained reagent Class I registration from China's NMPA for Bionano's DNA isolation products. Ecobono is Bionano’s third Chinese OEM ... Nov 29, 2023 · SAN DIEGO, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication demonstrating the use of optical genome mapping (OGM) to identify structural variations (SVs) introduced by CRISPR-Cas9 gene editing of CD4+ T-cells that could potentially limit the therapeutic use of such edited cells. May 10, 2023 · For full-year 2023, Bionano reiterated its revenue guidance of $35.0 million to $38.0 million. The company’s Q2 revenues are expected to be in the range of $7.8 million to $8.3 million. In early morning trading on the Nasdaq, Bionano's shares were up about 7 percent at $.79. Bionano Genomics, Inc. (NASDAQ:NASDAQ:BNGO) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ETCompany ParticipantsAmy Conrad - Investor RelationsErik Holmlin - Chief Executive...May 9, 2023 · Bionano Genomics. May 9, 2023 at 4:01 PM · 17 min read. Bionano Genomics. Q1 2023 revenue was $7.4 million, which represents a 30% increase over Q1 2022. Installed base of 259 Saphyr® systems ...

SAN DIEGO, April 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study from researchers at Radboud University Medical Center showing the use of optical genome mapping (OGM) to identify gene disruptive structural variants (SVs) that might contribute to inherited retinal diseases …

NEW YORK – Bionano Genomics said on Friday afternoon that the company is executing a 1-for-10 reverse stock split of its issued and outstanding common stock. The move will take effect at 5 p.m. Eastern Daylight Time on August 4, and the company's common stock will begin trading on a split-adjusted basis commencing upon market …

Following the downgrade, the current consensus from Bionano Genomics' five analysts is for revenues of US$40m in 2023 which - if met - would reflect a huge 53% increase on its sales over the past ...Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine.Latest news about Bionano Genomics, Inc. North American Morning Briefing : Caution -2- Nov. 14: DJ Transcript : Bionano Genomics, Inc., Q3 2023 Earnings Call, Nov 08, 2023 Nov. 08: CI Bionano Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 Nov. 08: CI Bionano …Os últimos tweets de @bionanogenomicsA big change in the C-suite was behind the steep fall in Bionano Genomics ' ( BNGO -12.27%) share price on Monday. Following the biotech's announcement that its CFO is stepping down, investors ...15 Jan 2021 ... That is the question for those investing in Bionano Genomics (NASDAQ: BNGO). ... The news comes on top of advances in coronavirus and in the ...Jan 10, 2023 · SAN DIEGO , Jan. 10, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics , Inc. (BNGO) today announced its 2023 Symposium, which is the quintessential event for the optical genome mapping (OGM) community to present its progress to the world. It will feature four consecutive days of OGM presentations The human body’s development can be a tricky business. Different DNA sequences and genomes all play huge roles in things like immune responses and neurological capacities. The genomes people possess are deciding factors in everything all th...Nov 8, 2023 · SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2023. Business Updates Since the End ... SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the publication by scientists at Revvity Omics (formerly Perkin Elmer Genomics), Leiden University Medical Centre, Bombay Hospital, and UT Dallas, of the largest peer-reviewed study to date on the use of optical genome mapping (OGM) to diagnose facioscapulohumeral muscular dystrophy (FSHD).

14 Okt 2021 ... 22, 2021. Source: Bionano Genomics. Related Content: Bio/Pharma News ...Company profile page for Bionano Genomics Inc including stock price, company news, press releases, executives, board members, and contact informationBionano Genomics, Inc. (NASDAQ: BNGO) seeks to enhance shareholder value not only through exceptional business performance and practices, but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual and institutional investor includes stock price and history, upcoming ... Instagram:https://instagram. easiest mortgage company to get approvedapple trialershelix energy stockwashington state short term health insurance SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication in Nature Communications demonstrating the utility of optical genome mapping (OGM) as an alternative to karyotyping (KT) and chromosomal microarray (CMA) for the evaluation of CRISPR-Cas9 edited human induced pluripotent stem cell (iPSC) lines in order to uncover possible pathogenic ... fund management coursesbest mortgage lenders in north carolina Headline. After Plunging -23.84% in 4 Weeks, Here's Why the Trend Might Reverse for Bionano Genomics, Inc. (BNGO) finance.yahoo.com - November 17 at 2:20 PM. Analysts Offer Insights on Healthcare Companies: BioNano Genomics (BNGO) and Ascendis Pharma (ASND) markets.businessinsider.com - November 16 at 11:51 PM.11 Jul 2023 ... BNGO stock is receiving lots of attention from retail investors, some who claim Bionano Genomics stock ... BREAKING NEWS - Bionano CFO Reveals Why ... luxury hotel reits Sep 14, 2023 · SAN DIEGO, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a study detailing the challenges associated with the detection and interpretation of causal variants in Mendelian disease, using a cohort of 4,577 families. The study authors conducted a comprehensive analysis of samples from ... BNGO | Complete Bionano Genomics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.